RxDoctor Payments Data

Courtnye Simmons

Nurse Practitioner · Montgomery, ALNPI 1407155369

Payments from drug & device makers

$1,007in general payments, 2019–2025

Across 52 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$112
  • Novartis$94
  • Otsuka America Pharmaceutical, Inc.$87
  • Sunovion Pharmaceuticals Inc.$74
  • Amneal Pharmaceuticals LLC$58
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$57
  • plus $525 from 19 others

What the payments were for

  • Food & beverage$1,007100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,007 in reported general payments places this provider in the 70th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$18,015
Medicare patients
189
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$47,244
OzempicSemaglutide32$45,251
JardianceEmpagliflozin32$35,362
MyrbetriqMirabegron54$31,983
LinzessLinaclotide17$15,936
TradjentaLinagliptin16$14,952
EntrestoSacubitril/Valsartan17$14,557
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,465
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$8,729
SymbicortBudesonide/Formoterol Fumarate34$8,415
Janumet XrSitagliptin Phos/Metformin Hcl11$6,163
Breo ElliptaFluticasone/Vilanterol14$5,852
MovantikNaloxegol Oxalate12$4,747
Colchicine13$2,466
Duloxetine Hcl63$1,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$32$50,31448 claims
PfizerEliquis$20$47,24450 claims
AbbVieLinzess$29$15,93617 claims
NovartisEntresto$94$14,55717 claims
AstraZenecaSymbicort$12$8,41534 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$58$1,43775 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →